Anthony Mirhaydari

InvestorPlace Market Strategist

Anthony Mirhaydari is founder of the Edge and Edge Pro investment advisory newsletters.

He is an independent investment columnist with work appearing at Investorplace, The Fiscal Times, CBS News MoneyWatch, MSN Money, Yahoo Finance, and Dow Jones MarketWatch. He started covering the markets and the economy in the media in 2008 in the midst of the greatest financial crisis in generations.

Previously, he was a senior research analyst with Markman Capital Insight, an advisory and money management firm, and a business consulting analyst with Moss Adams focusing on the financial-services industry.

Recent Articles

3 Big Stock Charts for Friday: Exxon Mobil Corporation (XOM), Goldcorp Inc. (USA) (GG) and Newmont Mining Corp (NEM)

By Anthony Mirhaydari, InvestorPlace Market Strategist Mar 18, 2016

The markets are feeling good after the Federal Reserve's "no hike," and that's reflected in Goldcorp (GG), Exxon Mobil (XOM) and Newmont (NEM).

Crude Retakes $40-A-Barrel as Post-Fed Rally Continues

By Anthony Mirhaydari, InvestorPlace Market Strategist Mar 17, 2016

In the end, the Dow Jones Industrial Average gained 0.9%, the S&P 500 rose 0.7%, the Nasdaq Composite added 0.2% and the Russell 2000 finished the day off 1.6% higher. T

3 Big Stock Charts for Thursday: Amazon.com, Inc. (AMZN), Netflix, Inc. (NFLX) and Twitter Inc (TWTR)

By Anthony Mirhaydari, InvestorPlace Market Strategist Mar 17, 2016

Amazon (AMZN), Netflix (NFLX) and Twitter (TWTR) are all starting to display disturbing charts -- part of a broader trend of big tech rolling over.

Dow Jones, Nasdaq Rebound as Fed Holds the Line

By Anthony Mirhaydari, InvestorPlace Market Strategist Mar 16, 2016

In the end, the Dow Jones Industrial Average gained 0.4%, the S&P 500 gained 0.6%, the Nasdaq Composite finished off 0.8% higher and the Russell 2000 ended the day with a 0.7% gain.

7 Big Pharma & Biotech Stocks to Sell or Short

By Anthony Mirhaydari, InvestorPlace Market Strategist Mar 16, 2016

Biotech stocks and Big Pharma look vulnerable to a toppy market. While these seven stocks aren't bad long-term bets, you may want to take some profits.